Novartis Inks $670M Deal For Kidney Treatment Drug
The deal grants Novartis an option to obtain an exclusive worldwide license to develop and commercialize the drug known as QPI-1002.
It is being developed to prevent acute kidney injury in patients undergoing major cardiovascular surgery, and to prevent a form of acute renal failure in patients receiving kidney transplants.
The drug, which is currently in Phase 2...
To view the full article, register now.